Combination therapy with anti-PD-1 and AAGL elicited stronger anti-tumor immune responses and resulted in longer lifetimes, thus overcoming the deficiency of immune cells in the tumor microenvironment in response to PD-1 blockade alone. The gene discussed is PDCD1; the disease is neoplasm.